Elanco Animal Health Incorporat (ELAN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.34
- Estimate
- $0.27
- Surprise
- +26.5%
- Revenue (period 2026-06-30)
- $1.37B
- Score at report (before → after)
- 4.9 → 4.9/10
Revenue source: xbrl.
How the report landed
Elanco Animal Health Incorporat (ELAN) beat the $0.27 estimate with adjusted EPS of $0.34 — a large 26.5% upside surprise. TrendMatrix's engine moved from Hold (4.9/10) to Buy (Wait) at 4.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ELAN Sell at 5.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +26.5% surprise compares with a +24.5% four-quarter average. Next scheduled report: 2026-11-06.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
- Negative momentum
- Momentum score 2.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $22.35
- Price target
- $27.16
- Stop
- $21.10
- Upside to target
- +21.5%
- Reward-to-risk
- 3.5:1
Risk check: RSI 23 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
ELAN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $11.27B
- P/E (fwd)
- 17.5
- 52-week range
- $18.48–$27.98
- Off 52-week high
- 20.1%
- RSI (14)
- 23
- Volume vs avg
- 1.42×
- Score today
- 5.4/10